Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

When An SPA Is Not Enough: FDA Will Consider Response Rate For Allos Drug

Executive Summary

The trial supporting the NDA for Allos Therapeutics' peripheral T-cell lymphoma drug pralatrexate was conducted under a Special Protocol Assessment with FDA - but that does not necessarily mean the magnitude of benefit shown will satisfy the agency
Advertisement

Related Content

Post-Market Trials Could Broaden Label For Allos' Newly Approved Folotyn
Post-Market Trials Could Broaden Label For Allos' Newly Approved Folotyn
Post-Market Requirements Could Broaden Label For Allos' Newly Approved PTCL Drug Folotyn
Analysts Hot, Investors Lukewarm On Allos’ Pralatrexate Phase II

Topics

Advertisement
UsernamePublicRestriction

Register

PS050927

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel